Aim of paper: To assess the incidence of adverse effects occurring in patients receiving intravenous and oral topotecan for ovarian cancer. Material and method: Clinical data on 21 patients treated for ovarian cancer at the Department of Surgical Gynecology of the K. Marcinkowski Medical University in Poznań, Poland, since 2007 thru 2009. Topotecan was administered intravenously at a dose of 1.5 mg/m²/d for 5 days, or orally at a dose of 2.3 mg/m²/d for 5 days. Analysis encompassed clinical and laboratory data related to 92 chemotherapy courses (39 intravenous and 53 oral). Results: In the intravenous group, grade 1 leucopenia was seen in 2 cases out of 39 courses (5.1%). In the oral group, there was 1 case of grade 1 leucopenia (1.9%) and 2 cases of grade 2 leucopenia out of 53 courses (3.8%). In the intravenous group, grade 1 anemia was noticed in 12 out of 39 courses (30.8%), grade 2 anemia – in 14 out of 39 courses (35.9%) and 1 case of grade 3 anemia (2.6%). In the oral group, grade 1 anemia occurred in 14 out of 53 courses (26.4%), grade 2 anemia – in 11 cases (20.8%) and grade 3 anemia – in 1 case (1.9%). No cases of grade 4 anemia or thrombocytopenia were recorded. Conclusions: In our population of patients treated for malignant tumors of the ovary, a similar rate of topotecan-associated hematologic complications was noticed after intravenous and oral administration of the drug.